Last $369.64 USD
Change Today +28.93 / 8.49%
Volume 2.5M
REGN On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 10/17/14 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for regeneron pharmaceuticals (REGN)

Year over year, Regeneron Pharmaceuticals, Inc. has seen their bottom line shrink from $750.3M USD to $424.4M USD despite an increase in revenues from $1.4B USD to $2.1B USD. An increase in the percentage of sales devoted to income tax expenses from -24.36% to 13.73% was a key component in the falling bottom line in the face of rising revenues.
Currency in
Millions of US Dollars
As of:Dec 31
2010
Restated
Dec 31
2011
Reclassified
Dec 31
2012
Dec 31
2013
4 Year
Trend
Revenues459.1445.81,378.52,104.7
TOTAL REVENUES459.1445.81,378.52,104.7
Cost of Goods Sold491.3533.7710.01,015.3
GROSS PROFIT-32.3-87.9668.51,089.4
Selling General & Admin Expenses, Total65.2117.3210.8329.4
OTHER OPERATING EXPENSES, TOTAL65.2117.3210.8329.4
OPERATING INCOME-97.5-205.2457.7760.0
Interest Expense-9.1-21.3-45.3-46.4
Interest and Investment Income2.13.52.0--
NET INTEREST EXPENSE-7.0-17.7-43.3-46.4
EBT, EXCLUDING UNUSUAL ITEMS-104.5-222.9414.4713.6
Gain (Loss) on Sale of Investments-------0.2
EBT, INCLUDING UNUSUAL ITEMS-104.5-222.9414.4713.4
Income Tax Expense---1.1-335.8289.0
Earnings from Continuing Operations-104.5-221.8750.3424.4
NET INCOME-104.5-221.8750.3424.4
NET INCOME TO COMMON INCLUDING EXTRA ITEMS-104.5-221.8750.3424.4
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS-104.5-221.8750.3424.4
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
REGN:US $369.64 USD +28.93

REGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alexion Pharmaceuticals Inc $164.75 USD +1.50
Allergan Inc/United States $177.49 USD -0.51
Jazz Pharmaceuticals PLC $152.36 USD +2.10
UCB SA €62.06 EUR -2.03
Vertex Pharmaceuticals Inc $102.35 USD +1.09
View Industry Companies
 

Industry Analysis

REGN

Industry Average

Valuation REGN Industry Range
Price/Earnings 100.0x
Price/Sales 14.9x
Price/Book 15.7x
Price/Cash Flow 94.3x
TEV/Sales 14.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENERON PHARMACEUTICALS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.